| Dr Paul W Schuppner, DO | |
|
1504 Madison Ave, Fort Atkinson, WI 53538-3100 | |
| (920) 563-7888 | |
| (920) 568-7741 |
| Full Name | Dr Paul W Schuppner |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 17 Years |
| Location | 1504 Madison Ave, Fort Atkinson, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215145206 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 60971-21 (Wisconsin) | Primary |
| 207X00000X | Orthopaedic Surgery | 5101017176 (Michigan) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fort Memorial Hospital | Fort atkinson, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fort Healthcare Inc | 0840189718 | 130 |
News Archive
Researchers have identified a protein in the brain that halts the progression of Alzheimer's disease in human brain tissue. The protein, known as "transthyretin," protects brain cells from gradual deterioration by blocking another toxic protein that contributes to the disease process.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
To predict severe outcome in COVID-19 patients, innate immune cellular signals are analyzed, identifying two novel neutrophil subsets: LOX-1- and CD123-expressing CD10-CD64+. Thromboembolic events correlated with high LOX-1 immature neutrophils – a potential prognostic signature.
A new study has shown that potent antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could help protect against COVID-19 infection. Preliminary results in animal studies have so far proven successful. The study titled, "Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model," was published in the latest issue of the journal Science.
› Verified 7 days ago
| Entity Name | Fort Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417993361 PECOS PAC ID: 0840189718 Enrollment ID: O20040319001411 |
News Archive
Researchers have identified a protein in the brain that halts the progression of Alzheimer's disease in human brain tissue. The protein, known as "transthyretin," protects brain cells from gradual deterioration by blocking another toxic protein that contributes to the disease process.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
To predict severe outcome in COVID-19 patients, innate immune cellular signals are analyzed, identifying two novel neutrophil subsets: LOX-1- and CD123-expressing CD10-CD64+. Thromboembolic events correlated with high LOX-1 immature neutrophils – a potential prognostic signature.
A new study has shown that potent antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could help protect against COVID-19 infection. Preliminary results in animal studies have so far proven successful. The study titled, "Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model," was published in the latest issue of the journal Science.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul W Schuppner, DO 1504 Madison Ave, Fort Atkinson, WI 53538-3100 Ph: (920) 563-7888 | Dr Paul W Schuppner, DO 1504 Madison Ave, Fort Atkinson, WI 53538-3100 Ph: (920) 563-7888 |
News Archive
Researchers have identified a protein in the brain that halts the progression of Alzheimer's disease in human brain tissue. The protein, known as "transthyretin," protects brain cells from gradual deterioration by blocking another toxic protein that contributes to the disease process.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
To predict severe outcome in COVID-19 patients, innate immune cellular signals are analyzed, identifying two novel neutrophil subsets: LOX-1- and CD123-expressing CD10-CD64+. Thromboembolic events correlated with high LOX-1 immature neutrophils – a potential prognostic signature.
A new study has shown that potent antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could help protect against COVID-19 infection. Preliminary results in animal studies have so far proven successful. The study titled, "Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model," was published in the latest issue of the journal Science.
› Verified 7 days ago
Matthew S Bliss, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1504 Madison Ave, Fort Atkinson, WI 53538 Phone: 920-563-7888 Fax: 920-563-7741 | |
Isidoro V Zambrano, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1504 Madison Ave, Fort Atkinson, WI 53538 Phone: 920-563-7888 Fax: 920-563-7741 | |
Thomas J Nordland, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 1504 Madison Ave, Fort Atkinson, WI 53538 Phone: 920-563-7888 Fax: 920-563-7741 | |
Stanley E Peterson, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 426 Mcmillen St, Fort Atkinson, WI 53538 Phone: 920-563-7888 Fax: 920-563-7741 |